This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Social Bookmarking   What's this?

Analysis of Pooled Data From Five Randomized Controlled Trials

Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study

Arch Intern Med. 1994;154(13):1449-1457.

Abstract
Background and Methods
Atrial fibrillation is associated with an increased risk of ischemic stroke. Data on individual patients were pooled from five recently completed randomized trials comparing warfarin (all studies) or aspirin (the Atrial Fibrillation, Aspirin, Anticoagulation Study and the Stroke Prevention in Atrial Fibrillation Study) with control in patients with atrial fibrillation. The purpose of the analysis was to (1) identify patient features predictive of a high or low risk of stroke, (2) assess the efficacy of antithrombotic therapy in major patient subgroups (eg, women), and (3) obtain the most precise estimate of the efficacy and risks of antithrombotic therapy in atrial fibrillation. For the warfarin-control comparison there were 1889 patient-years receiving warfarin and 1802 in the control group. For the aspirin-placebo comparison there were 1132 patient-years receiving aspirin and 1133 receiving placebo. The daily dose of aspirin was 75 mg in the Atrial Fibrillation, Aspirin, Anticoagulation Study and 325 mg in the Stroke Prevention in Atrial Fibrillation Study. To monitor warfarin dosage, three studies used prothrombin time ratios and two used international normalized ratios. The lowest target intensity was a prothrombin time ratio of 1.2 to 1.5 and the highest target intensity was an international normalized ratio of 2.8 to 4.2. The primary end points were ischemic stroke and major hemorrhage, as assessed by each study.

Results
At the time of randomization the mean age was 69 years and the mean blood pressure was 142/82 mm Hg. Forty-six percent of the patients had a history of hypertension, 6% had a previous transient ischemic attack or stroke, and 14% had diabetes. Risk factors that predicted stroke on multivariate analyses in control patients were increasing age, history of hypertension, previous transient ischemic attack or stroke, and diabetes. Patients younger than 65 years who had none of the other predictive factors (15% of all patients) had an annual rate of stroke of 1.0%, 95% confidence interval (CI) 0.3% to 3.0%. The annual rate of stroke was 4.5% for the control group and 1.4% for the warfarin group (risk reduction, 68%; 95% CI, 50% to 79%). The efficacy of warfarin was consistent across all studies and subgroups of patients. In women, warfarin decreased the risk of stroke by 84% (95% CI, 55% to 95%) compared with 60% (95% CI, 35% to 76%) in men. The efficacy of aspirin was not as consistent. The risk reduction with 75 mg of aspirin in the Atrial Fibrillation, Aspirin, Anticoagulation Study was 18% (95% CI, 60% to 58%), and with 325 mg of aspirin in the Stroke Prevention in Atrial Fibrillation Study the risk reduction was 44% (95% CI, 7% to 66%). When both studies were combined the risk reduction was 36% (95% CI, 4% to 57%). The annual rate of major hemorrhage (intracranial bleeding or a bleed requiring hospitalization or 2 units of blood) was 1.0% for the control group, 1.0% for the aspirin group, and 1.3% for the warfarin group.

Conclusion
In these five randomized trials warfarin consistently decreased the risk of stroke in patients with atrial fibrillation (a 68% reduction in risk) with virtually no increase in the frequency of major bleeding. Patients with atrial fibrillation younger than 65 years without a history of hypertension, previous stroke or transient ischemic attack, or diabetes were at very low risk of stroke even when not treated. The efficacy of aspirin was less consistent. Further studies are needed to clarify the role of aspirin in atrial fibrillation.

(Arch Intern Med. 1994;154:1449-1457)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

The Underuse of Warfarin Treatment in the Elderly
Valery A. Portnoi, Lawrence M. Brass, Harlan M. Krumholz, Jeanne D. Scinto, Deepak Mathur, and Martha Radford
Arch Intern Med. 1999;159(12):1374-1375.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chagas Disease: Independent Risk Factor for Stroke
Paixao et al.
Stroke 2009;40:3691-3694.
ABSTRACT | FULL TEXT  

Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood et al.
J Am Coll Cardiol 2009;54:2023-2031.
ABSTRACT | FULL TEXT  

Perioperative management of warfarin and antiplatelet therapy
JAFFER
Cleveland Clinic Journal of Medicine 2009;76:S37-S44.
ABSTRACT | FULL TEXT  

Cerebral Microbleeds in Ischemic Stroke Patients on Warfarin Treatment
Orken et al.
Stroke 2009;40:3638-3640.
ABSTRACT | FULL TEXT  

The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
Glotzer et al.
Circ Arrhythm Electrophysiol 2009;2:474-480.
ABSTRACT | FULL TEXT  

Quality of care for atrial fibrillation among patients hospitalized for heart failure.
Piccini et al.
J Am Coll Cardiol 2009;54:1280-1289.
ABSTRACT | FULL TEXT  

Reducing Stroke Rates in Patients With Atrial Fibrillation: How Low Can We Go?
Ezekowitz et al.
Circulation 2009;120:1169-1170.
FULL TEXT  

Concurrent prophylactic left atrial appendage exclusion: results from a randomized controlled trial pilot study
Nagpal et al.
Eur. J. Cardiothorac. Surg. 2009;36:553-557.
ABSTRACT | FULL TEXT  

The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Singer et al.
ANN INTERN MED 2009;151:297-305.
ABSTRACT | FULL TEXT  

Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction: A Prospective Study of 4202 Patients
Torn et al.
Arch Intern Med 2009;169:1203-1209.
ABSTRACT | FULL TEXT  

Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study
Singer et al.
Circ Cardiovasc Qual Outcomes 2009;2:297-304.
ABSTRACT | FULL TEXT  

Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Crandall et al.
Mayo Clin Proc. 2009;84:643-662.
ABSTRACT | FULL TEXT  

Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation
Hart and Pearce
Stroke 2009;40:2607-2610.
FULL TEXT  

Left Atrial Appendage Thrombi in Stroke Patients: Detection with Two-Phase Cardiac CT Angiography versus Transesophageal Echocardiography
Hur et al.
Radiology 2009;251:683-690.
ABSTRACT | FULL TEXT  

Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis
Feng et al.
Circulation 2009;119:2490-2497.
ABSTRACT | FULL TEXT  

Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation
Kim et al.
The Annals of Pharmacotherapy 2009;43:840-848.
ABSTRACT | FULL TEXT  

Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score
Kleemann et al.
Eur J Echocardiogr 2009;10:383-388.
ABSTRACT | FULL TEXT  

Assessment of left atrial appendage function with transthoracic tissue Doppler echocardiography
Uretsky et al.
Eur J Echocardiogr 2009;10:363-371.
ABSTRACT | FULL TEXT  

Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators
van Walraven et al.
Stroke 2009;40:1410-1416.
ABSTRACT | FULL TEXT  

Sex Differences in Stroke Epidemiology: A Systematic Review
Appelros et al.
Stroke 2009;40:1082-1090.
ABSTRACT | FULL TEXT  

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial
Massie et al.
Circulation 2009;119:1616-1624.
ABSTRACT | FULL TEXT  

Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Go et al.
Circulation 2009;119:1363-1369.
ABSTRACT | FULL TEXT  

Thrombosis and Antithrombotic Therapy in Women
Bailey et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:284-288.
ABSTRACT | FULL TEXT  

Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation
Friberg et al.
Eur Heart J 2009;0:ehn599v1-9.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
Eckman et al.
ANN INTERN MED 2009;150:73-83.
ABSTRACT | FULL TEXT  

Anticoagulation in patients with heart failure and normal sinus rhythm
Ripley and Nutescu
Am J Health Syst Pharm 2009;66:134-141.
ABSTRACT | FULL TEXT  

Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage
Lee et al.
Neurology 2009;72:171-176.
ABSTRACT | FULL TEXT  

Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
Gladstone et al.
Stroke 2009;40:235-240.
ABSTRACT | FULL TEXT  

CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation: How Will Screening With Genetics and Imaging Help? * Supplemental Appendix
Eckman et al.
Stroke 2008;39:3308-3315.
ABSTRACT | FULL TEXT  

Severe Left Atrial Appendage Stunning After Electrical Cardioversion of Atrial Fibrillation
Melduni et al.
Circulation 2008;118:e699-e700.
FULL TEXT  

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Connolly et al.
Circulation 2008;118:2029-2037.
ABSTRACT | FULL TEXT  

Intermediate to Long-Term Results of Radiofrequency Modified Maze Procedure as an Adjunct to Open-Heart Surgery
Beukema et al.
Ann. Thorac. Surg. 2008;86:1409-1414.
ABSTRACT | FULL TEXT  

Anticoagulation Control in Atrial Fibrillation: Optimizing Risks and Benefits
Alsheikh-Ali and Estes
Circ Cardiovasc Qual Outcomes 2008;1:72-73.
FULL TEXT  

Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V
Hylek et al.
Stroke 2008;39:3009-3014.
ABSTRACT | FULL TEXT  

Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage
Claassen et al.
Arch Neurol 2008;65:1313-1318.
ABSTRACT | FULL TEXT  

Racial/Ethnic Differences in Ischemic Stroke Rates and the Efficacy of Warfarin Among Patients With Atrial Fibrillation
Shen et al.
Stroke 2008;39:2736-2743.
ABSTRACT | FULL TEXT  

Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention
Lip
BMJ 2008;337:a840-a840.
FULL TEXT  

Success of Surgical Left Atrial Appendage Closure: Assessment by Transesophageal Echocardiography
Kanderian et al.
J Am Coll Cardiol 2008;52:924-929.
ABSTRACT | FULL TEXT  

Epidemiology, Risk Factors for Stroke, and Management of Atrial Fibrillation in China
Hu and Sun
J Am Coll Cardiol 2008;52:865-868.
FULL TEXT  

Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention
Choudhury et al.
Chest 2008;134:574-581.
ABSTRACT | FULL TEXT  

Review: Stroke prevention: modifying risk factors
Romero et al.
Ther Adv Cardiovasc Dis 2008;2:287-303.
ABSTRACT  

Prognostic models
Rothwell
PN 2008;8:242-253.
ABSTRACT | FULL TEXT  

Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world
Meiltz et al.
Europace 2008;10:674-680.
ABSTRACT | FULL TEXT  

Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation
Wysokinski et al.
Mayo Clin Proc. 2008;83:639-645.
ABSTRACT | FULL TEXT  

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Albers et al.
Chest 2008;133:630S-669S.
ABSTRACT | FULL TEXT  

Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke Risk in Atrial Fibrillation Working Group
Stroke 2008;39:1901-1910.
ABSTRACT | FULL TEXT  

Atrial Fibrillation and Isolated Systolic Hypertension: The Systolic Hypertension in the Elderly Program and Systolic Hypertension in the Elderly Program-Extension Study
Vagaonescu et al.
Hypertension 2008;51:1552-1556.
ABSTRACT | FULL TEXT  

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Healey et al.
Stroke 2008;39:1482-1486.
ABSTRACT | FULL TEXT  

Isolating the entire posterior left atrium improves surgical outcomes after the Cox maze procedure.
Voeller et al.
J. Thorac. Cardiovasc. Surg. 2008;135:870-877.
ABSTRACT | FULL TEXT  

Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Nieuwlaat et al.
Eur Heart J 2008;29:915-922.
ABSTRACT | FULL TEXT  

Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls
Garwood and Corbett
The Annals of Pharmacotherapy 2008;42:523-532.
ABSTRACT | FULL TEXT  

Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation
Fang et al.
J Am Coll Cardiol 2008;51:810-815.
ABSTRACT | FULL TEXT  

Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation
Weintraub
J Am Coll Cardiol 2008;51:816-817.
FULL TEXT  

ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society
Estes et al.
J Am Coll Cardiol 2008;51:865-884.
FULL TEXT  

ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation)
Estes et al.
Circulation 2008;117:1101-1120.
FULL TEXT  

Age alone is not a risk factor for left atrial thrombus in atrial fibrillation
Mazouz et al.
Heart 2008;94:197-199.
ABSTRACT | FULL TEXT  

Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation
Duygu et al.
Europace 2008;10:210-214.
ABSTRACT | FULL TEXT  

New oral anticoagulants in atrial fibrillation
Turpie
Eur Heart J 2008;29:155-165.
ABSTRACT | FULL TEXT  

Surgical Treatment of Atrial Fibrillation
Voeller et al.
Card Surg Adult 2008;3:1375-1394.
FULL TEXT  

Major Bleeding in Hemodialysis Patients
Holden et al.
CJASN 2008;3:105-110.
ABSTRACT | FULL TEXT  

Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Substudy
Hohnloser et al.
J Am Coll Cardiol 2007;50:2156-2161.
ABSTRACT | FULL TEXT  

Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis
Feng et al.
Circulation 2007;116:2420-2426.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation
Nutescu
Am J Health Syst Pharm 2007;64:2281-2291.
FULL TEXT  

Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials
Ford et al.
Stroke 2007;38:2965-2971.
ABSTRACT | FULL TEXT  

Noninvasive Cardiac Monitoring for Detecting Paroxysmal Atrial Fibrillation or Flutter After Acute Ischemic Stroke: A Systematic Review
Liao et al.
Stroke 2007;38:2935-2940.
ABSTRACT | FULL TEXT  

REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Circulation 2007;116:e391-e413.
ABSTRACT | FULL TEXT  

Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review
Hughes et al.
QJM 2007;100:599-607.
ABSTRACT | FULL TEXT  

Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation
Habara et al.
Eur Heart J 2007;28:2217-2222.
ABSTRACT | FULL TEXT  

Perindopril and prevention of atrial fibrillation
Tardif and Talajic
Eur Heart J Suppl 2007;9:E25-E29.
ABSTRACT | FULL TEXT  

Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Baruch et al.
Stroke 2007;38:2459-2463.
ABSTRACT | FULL TEXT  

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial
Fitzmaurice et al.
BMJ 2007;335:383-383.
ABSTRACT | FULL TEXT  

Independent predictors of stroke in patients with atrial fibrillation: A systematic review
The Stroke Risk in Atrial Fibrillation Working Gro
Neurology 2007;69:546-554.
ABSTRACT | FULL TEXT  

A Cautionary Note on Data Sources for Evidence-Based Clinical Decisions: Warfarin and Stroke Prevention
Thomson et al.
Med Decis Making 2007;27:438-447.
ABSTRACT  

Racial/Ethnic Differences in the Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation
Shen et al.
J Am Coll Cardiol 2007;50:309-315.
ABSTRACT | FULL TEXT  

Coronary Artery Disease and Ischemic Stroke in Atrial Fibrillation
Lip
Chest 2007;132:8-10.
FULL TEXT  

Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation: A 30-Year Follow-Up Study
Jahangir et al.
Circulation 2007;115:3050-3056.
ABSTRACT | FULL TEXT  

The time horizons of formal decision analyses
Benbassat and Baumal
QJM 2007;100:383-388.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Stroke 2007;38:2001-2023.
ABSTRACT | FULL TEXT  

Bleeding While Starting Anticoagulation for Thromboembolism Prophylaxis in Elderly Patients With Atrial Fibrillation: From Bad to Worse
Wyse
Circulation 2007;115:2684-2686.
FULL TEXT  

Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Hylek et al.
Circulation 2007;115:2689-2696.
ABSTRACT | FULL TEXT  

Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial
Holbrook et al.
CMAJ 2007;176:1583-1587.
ABSTRACT | FULL TEXT  

Platelet Surface CD62P and CD63, Mean Platelet Volume, and Soluble/Platelet P-Selectin as Indexes of Platelet Function in Atrial Fibrillation: A Comparison of "Healthy Control Subjects" and "Disease Control Subjects" in Sinus Rhythm
Choudhury et al.
J Am Coll Cardiol 2007;49:1957-1964.
ABSTRACT | FULL TEXT